Government panel National Technical Advisory Group on Immunisation (NTAGI) has recommended increasing the gap between two doses of Covishield to 12-16 weeks, unlike the earlier 8-week gap, while at the same time suggesting no change in the Covaxin dosage interval.
Furthermore, the body has also recommended that those testing positive for Covid-19 should defer their vaccination for at least six months after their recovery.
NTAGI also suggested that “pregnant women may be offered the choice to take any Covid-19 vaccine, while lactating women are eligible for jabs any time after the delivery”.
Earlier today, the Drugs Controller General of India (DCGI) granted its approval for the Phase 2 and Phase 3 clinical trials of Bharat Biotech’s Covid-19 vaccine – Covaxin – in the age group of 2-18 years.
The firm will reportedly carry out these trials on 525 healthy volunteers.
“After detailed deliberation, the committee recommended for conduct of proposed Phase II/III clinical trial of the whole virion inactivated coronavirus vaccine in the 2 to 18 years age group subject to the condition that the firm should submit the interim safety data of phase II clinical trial along with DSMB recommendations to the CDSCO before proceeding to phase III part of the study,”
Journalists to categorize Frontline workers Maharashtra Minister appeals to CM
Manish Sisodia says positivity rate declines in Delhi, beds also empty in hospitals
Corona now hunting animals after humans, infected nearly 10 lions in the country